Avery Therapeutics, Inc.
Biotechnology company focused on developing immunomodulatory biologic therapeutics for diseases of aging, inflammation, fibrosis and heart failure, using tissue-engineering approaches and cell-derived grafts.
Industries
Nr. of Employees
small (1-50)
Products
Adaptive immunomodulatory biologic platform (bioengineered cardiac patch and cell-derived grafts)
Platform combining bioengineered tissue patches and cell-derived grafts intended to modulate immune responses and promote cardiac repair in preclinical models.
Adaptive immunomodulatory biologic platform (bioengineered cardiac patch and cell-derived grafts)
Platform combining bioengineered tissue patches and cell-derived grafts intended to modulate immune responses and promote cardiac repair in preclinical models.
Expertise Areas
- Immunomodulatory biologic development
- Cardiac regenerative medicine
- Tissue engineering and biomaterials
- Preclinical translational research
Key Technologies
- Immunomodulatory biologics
- Bioengineered epicardial patch
- Tissue scaffold fabrication
- Induced pluripotent stem cell-derived cardiomyocytes
News & Updates
Article about immune modulation as a treatment approach for heart failure (authors include company leadership and collaborators).
Preclinical study reporting macrophage-mediated repair induced by a biologically derived epicardial patch in a chronic swine infarct model.
Rationale and proposed Phase I clinical trial design for a bioengineered cardiac patch.
Methodology and application of free-breathing CMR for imaging in a swine heart-failure model.
Preclinical study of an epicardially placed cardiomyocyte xenograft in an immune-competent rat model.
Perspective on cell-based surgical approaches using engineered tissue for heart failure.
Article about immune modulation as a treatment approach for heart failure (authors include company leadership and collaborators).
Preclinical study reporting macrophage-mediated repair induced by a biologically derived epicardial patch in a chronic swine infarct model.
Rationale and proposed Phase I clinical trial design for a bioengineered cardiac patch.
Methodology and application of free-breathing CMR for imaging in a swine heart-failure model.
Preclinical study of an epicardially placed cardiomyocyte xenograft in an immune-competent rat model.
Perspective on cell-based surgical approaches using engineered tissue for heart failure.